Betaseron for secondary-progressive MS?The large European European emanating from or pertaining to Europe. European bat lyssavirus see lyssavirus. European beech tree fagussylvaticus. European blastomycosis see cryptococcosis. trial of Betaseron in people with secondary-progressive MS produced encouraging data which were also published in The Lancet lancet /lan·cet/ (lan´set) a small, pointed, two-edged surgical knife. lan·cet n. last November. (Secondary-progressive MS begins as relapsing-remitting disease but later becomes progressive and worsens steadily.) Betaseron is now an approved treatment for secondary-progressive MS in Europe. Since the U.S. clinical trials leading to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Betaseron and Avonex didn't include people with this type of MS, secondary-progressive MS is not covered not covered Health care adjective Referring to a procedure, test or other health service to which a policy holder or insurance beneficiary is not entitled under the terms of the policy or payment system–eg, Medicare. Cf Covered. in the FDA approval. The FDA is currently reviewing these data and, it is hoped, will approve Betaseron for eligible people with secondary-progressive MS. See InsideMS, Fall 1998, page 39, for details on the reported benefits. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion